CoChat

High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease

Open access
Gordon, Elizabeth M., Figueroa, Debbie M., Barochia, Amisha V., Yao, Xianglan, Levine, Stewart J. · 2016 · Frontiers in Pharmacology
Cited by 108

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Apolipoprotein A-I (apoA-I) and high-density lipoproteins (HDL) mediate reverse cholesterol transport out of cells. Furthermore, HDL has additional protective functions, which include anti-oxidative, anti-inflammatory, anti-apoptotic, and vasoprotective effects. In contrast, HDL can become dysfunctional with a reduction in both cholesterol efflux and anti-inflammatory properties in the setting of disease or the acute phase response. These paradigms are increasingly being recognized to be active in the pulmonary system, where apoA-I and HDL have protective effects in normal lung health, as well as in a variety of disease states, including acute lung injury (ALI), asthma, chronic obstructive pulmonary disease, lung cancer, pulmonary arterial hypertension, pulmonary fibrosis, and viral pneumonia. Similar to observations in cardiovascular disease, however, HDL may become dysfunctional and contribute to disease pathogenesis in respiratory disorders. Furthermore, synthetic apoA-I mimetic peptides have been shown to have protective effects in animal models of ALI, asthma, pulmonary hypertension, and influenza pneumonia. These findings provide evidence to support the concept that apoA-I mimetic peptides might be developed into a new treatment that can either prevent or attenuate the manifestations of lung diseases, such as asthma. Thus, the lung is positioned to take a page from the cardiovascular disease playbook and utilize the protective properties of HDL and apoA-I as a novel therapeutic approach.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2016.00323

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 56

  1. Barochia, 2016, Serum high density lipoprotein cholesterol and large HDL particles are negatively correlated with blood eosinophils in atopic asthma., Am. J. Resp. Crit. Care Med., 193
  2. Barochia, 2015, Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma., Am. J. Resp. Crit. Care Med., 191, 990, 10.1164/rccm.201411-1990OC · DOI
  3. Bates, 2005, Pulmonary abnormalities due to abca1 deficiency in mice., Am. J. Physiol. Lung Cell Mol. Physiol., 289, L980, 10.1152/ajplung.00234.2005 · DOI
  4. Bates, 2008, Expression and biological activity of ABCA1 in alveolar epithelial cells., Am. J. Respir. Cell Mol. Biol., 38, 283, 10.1165/rcmb.2007-0020OC · DOI
  5. Bloedon, 2008, Safety, pharmacokinetics, and pharmacodynamics of oral apoa-i mimetic peptide D-4F in high-risk cardiovascular patients., J. Lipid Res., 49, 1344, 10.1194/jlr.P800003-JLR200 · DOI · Paper page
  6. Bortnick, 2003, Identification and characterization of rodent ABCA1 in isolated type II pneumocytes., Am. J. Physiol. Lung Cell Mol. Physiol., 285, L869, 10.1152/ajplung.00077.2003 · DOI
  7. Burkart, 2014, ApoM and high-density lipoprotein cholesterol are associated with lung function and per cent emphysema., Eur. Respir. J., 43, 1003, 10.1183/09031936.00147612 · DOI
  8. Catapano, 2014, HDL in innate and adaptive immunity., Cardiovasc. Res., 103, 372, 10.1093/cvr/cvu150 · DOI · Paper page
  9. Celli, 2015, An official american thoracic society/european respiratory society statement: research questions in chronic obstructive pulmonary disease., Am. J. Respir. Crit. Care Med., 191, e4, 10.1164/rccm.201501-0044ST · DOI · Paper page
  10. Chandler, 2016, Lipid biomarkers and long-term risk of cancer in the women’s health study., Am. J. Clin. Nutr., 103, 1397, 10.3945/ajcn.115.124321 · DOI · Paper page
  11. Chi, 2014, High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with c-reactive protein level in non-small cell lung carcinoma., PLoS ONE, 9, 10.1371/journal.pone.0091080 · DOI
  12. Cirillo, 2002, Lipids and pulmonary function in the third national health and nutrition examination survey., Am. J. Epidemiol., 155, 842, 10.1093/aje/155.9.842 · DOI
  13. Cote, 2011, Apolipoprotein A-I, A-II, and H mRNA and protein accumulation sites in the developing lung in late gestation., BMC Res. Notes, 4, 10.1186/1756-0500-4-235 · doi:10.1186/1756-0500-4-235
  14. Dai, 2012, Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism., Am. J. Respir. Cell Mol. Biol., 47, 186, 10.1165/rcmb.2011-0322OC · DOI
  15. Dai, 2014, ATP-binding cassette transporter 1 attenuates ovalbumin-induced neutrophilic airway inflammation., Am. J. Respir. Cell Mo.l Biol., 51, 626, 10.1165/rcmb.2013-0264OC · DOI
  16. Delvecchio, 2008, LXR-induced reverse cholesterol transport in human airway smooth muscle is mediated exclusively by ABCA1., Am. J. Physiol. Lung. Cell Mol. Physiol., 295, L949, 10.1152/ajplung.90394.2008 · DOI
  17. Dunbar, 2007, Daily oral administration of the apolipoprotein A-I mimetic peptide D-4F in patients with heart disease or equivalent risk improves high-density lipoprotein anti-inflammatory function (abstract)., J. Am. Coll. Cardiol., 49
  18. Emancipator, 1992, In vitro inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins., Infect. Immun., 60, 596, 10.1128/IAI.60.2.596-601.1992 · DOI · Paper page
  19. Hao, 2014, Haplotype analysis of apoAI gene and sepsis-associated acute lung injury., Lipids Health Dis., 13, 10.1186/1476-511X-13-79 · DOI
  20. Henning, 2011, Contribution of the c-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect., Innate Immun., 17, 327, 10.1177/1753425910370709 · DOI
  21. Heresi, 2010, Plasma levels of high-density lipoprotein cholesterol and outcomes in pulmonary arterial hypertension., Am. J. Respir. Crit. Care Med., 182, 661, 10.1164/rccm.201001-0007OC · DOI
  22. Jiao, 2008, Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid., Cytokine, 43, 83, 10.1016/j.cyto.2008.04.002 · DOI
  23. Kim, 2016, Attenuation of cigarette smoke-induced emphysema in mice by apolipoprotein A-1 overexpression., Am. J. Respir. Cell Mol. Biol., 54, 91, 10.1165/rcmb.2014-0305OC · DOI
  24. Kim, 2010, Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis., Am. J. Respir. Crit. Care Med., 182, 633, 10.1164/rccm.200905-0659OC · DOI · Paper page
  25. Kucharska-Newton, 2008, HDL-cholesterol and the incidence of lung cancer in the atherosclerosis risk in communities (ARIC) study., Lung Cancer, 61, 292, 10.1016/j.lungcan.2008.01.015 · DOI
  26. Kwon, 2012, 4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats., J. Trauma Acute Care Surg., 72, 1576, 10.1097/TA.0b013e3182493ab4 · DOI
  27. Lee, 2013, Overexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosis., PLoS ONE, 8, 10.1371/journal.pone.0055827 · DOI
  28. Li, 2008, Human apoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice., Eur. J. Pharmacol., 590, 417, 10.1016/j.ejphar.2008.06.047 · DOI
  29. Ma, 2004, Role of apolipoprotein A-I in protecting against endotoxin toxicity., Acta Biochim. Biophys. Sin., 36, 419, 10.1093/abbs/36.6.419 · DOI
  30. Madenspacher, 2012, Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity., J. Biol. Chem., 287, 43730, 10.1074/jbc.M112.377192 · DOI
  31. Matute-Bello, 1997, Neutrophil apoptosis in the acute respiratory distress syndrome., Am. J. Respir. Crit. Care Med., 156, 1969, 10.1164/ajrccm.156.6.96-12081 · DOI · Paper page
  32. McNeish, 2000, High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1., Proc. Natl. Acad. Sci. U.S.A., 97, 4245, 10.1073/pnas.97.8.4245 · DOI · Paper page
  33. Mora, 2010, Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women., Diabetes, 59, 1153, 10.2337/db09-1114 · DOI · Paper page
  34. Moreno, 2014, High-density lipoproteins potentiate alpha1-antitrypsin therapy in elastase-induced pulmonary emphysema., Am. J. Respir. Cell Mol. Biol., 51, 536, 10.1165/rcmb.2013-0103OC · DOI
  35. Nandedkar, 2011, D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma., J. Lipid Res., 52, 499, 10.1194/jlr.M012724 · DOI
  36. Navab, 2011, HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms., Nat. Rev. Cardiol., 8, 222, 10.1038/nrcardio.2010.222 · DOI · Paper page
  37. Nicholas, 2010, Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease., Am. J. Respir. Crit. Care Med., 181, 1049, 10.1164/rccm.200906-0857OC · DOI · Paper page
  38. Ortiz-Munoz, 2009, HDL antielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property., FASEB J., 23, 3129, 10.1096/fj.08-127928 · DOI
  39. Park, 2013, Apolipoprotein a1 potentiates lipoxin a4 synthesis and recovery of allergen-induced disrupted tight junctions in the airway epithelium., Clin. Exp. Allergy, 43, 914, 10.1111/cea.12143 · DOI
  40. Provost, 2009, Apolipoprotein A-I, A-II, C-II, and H expression in the developing lung and sex difference in surfactant lipids., J. Endocrinol., 200, 321, 10.1677/JOE-08-0238 · DOI
  41. Rastogi, 2015, Inflammation, metabolic dysregulation, and pulmonary function among obese urban adolescents with asthma., Am. J. Respir. Crit. Care Med., 191, 149, 10.1164/rccm.201409-1587OC · DOI · Paper page
  42. Ross, 2015, Proinflammatory high-density lipoprotein results from oxidized lipid mediators in the pathogenesis of both idiopathic and associated types of pulmonary arterial hypertension., Pulm. Circ., 5, 640, 10.1086/683695 · DOI
  43. Sharifov, 2013, Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis., PLoS ONE, 8, 10.1371/journal.pone.0064486 · DOI
  44. Sharma, 2014, Apolipoprotein A-I mimetic peptide 4F rescues pulmonary hypertension by inducing microrna-193-3p., Circulation, 130, 776, 10.1161/CIRCULATIONAHA.114.007405 · doi:10.1161/circulationaha.114.007405
  45. Smith, 1992, Polymorphism in the human apolipoprotein A-I gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro., J. Clin. Invest., 89, 1796, 10.1172/JCI115783 · DOI
  46. Tu, 2013, Association of apolipoprotein a1 -75 G/A polymorphism with susceptibility to the development of acute lung injury after cardiopulmonary bypass surgery., Lipids Health Dis., 12, 10.1186/1476-511X-12-172 · doi:10.1186/1476-511x-12-172
  47. Van Lenten, 2002, Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide., Circulation, 106, 1127, 10.1161/01.CIR.0000030182.35880.3E · DOI · Paper page
  48. Van Lenten, 2004, D-4F, an apolipoprotein a-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes., Circulation, 110, 3252, 10.1161/01.CIR.0000147232.75456.B3 · DOI · Paper page
  49. Van Lenten, 2001, High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection., Circulation, 103, 2283, 10.1161/01.CIR.103.18.2283 · DOI · Paper page
  50. Van Linthout, 2011, Down-regulation of endothelial TLR4 signalling after apo A-I gene transfer contributes to improved survival in an experimental model of lipopolysaccharide-induced inflammation., J. Mol. Med., 89, 151, 10.1007/s00109-010-0690-6 · DOI
  51. Wang, 2010, Genetic deletion of apolipoprotein a-i increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung., J. Lipid Res., 51, 2560, 10.1194/jlr.M004549 · DOI
  52. Watson, 2011, Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function., J. Lipid Res., 52, 361, 10.1194/jlr.M011098 · DOI · Paper page
  53. Xiao, 2008, High-density lipoprotein attenuates lipopolysaccharide-induced acute lung injury in mice., Sheng Li Xue Bao, 60, 403
  54. Yan, 2006, Beneficial effects of apoA-I on LPS-induced acute lung injury and endotoxemia in mice., Life Sci., 79, 210, 10.1016/j.lfs.2006.02.011 · DOI
  55. Yao, 2011, 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma., J. Immunol., 186, 576, 10.4049/jimmunol.1001534 · DOI · Paper page
  56. Zamanian-Daryoush, 2013, The cardioprotective protein apolipoprotein A1 promotes potent anti-tumorigenic effects., J. Biol. Chem., 288, 21237, 10.1074/jbc.M113.468967 · DOI · Paper page

Cited by

See all 108

Metadata

Authors
Gordon, E. M., Figueroa, D. M., Barochia, A. V., Yao, X., & Levine, S. J.
Venue
Frontiers in Pharmacology
Published
2016-09-21
Volume
7
Pages
323-323
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2522121027
Cited by
108
References
7
FWCI
13.61
Type
journal article
Language
en
Open access
gold
Funders
National Heart, Lung, and Blood Institute (1 ZIA HL006053 06, 1 ZIA HL006054 06)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease. https://app.cochat.ai/papers/10.3389/fphar.2016.00323
The paper
Gordon, E. M., Figueroa, D. M., Barochia, A. V., Yao, X., & Levine, S. J. (2016). High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2016.00323

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.